J&J Hard at Work on Additional COVID-19 Vaccines
Johnson & Johnson (J&J) is continuing to develop new COVID-19 vaccines to provide protection against a host of SARS-CoV-2 variants. Currently on the pharmaceutical giant’s agenda is creating a vaccine to combat the South African variant, B1351, which is more frequently found among young, healthy people and can cause more serious illness than the original strain of the novel coronavirus. A two-shot COVID-19 vaccine and boosters to its current one-shot immunization are also in the works. Click here to read more.